Descriptive characteristics at initiation of second-line TB treatment of RR-TB patients.

<p>Descriptive characteristics at initiation of second-line TB treatment of RR-TB patients.</p

South African National Department of Health policy on eligibility for decentralized drug-resistant TB care.

<p>South African National Department of Health policy on eligibility for decentralized drug-resistant TB care.</p

Description of cohort.

<p>Description of cohort.</p

TB disease of RR-TB patients at enrolment.

<p>TB disease of RR-TB patients at enrolment.</p

Relative risk^* and 95% confidence intervals of dying or being lost from treatment.

<p>Relative risk^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0164974#t005fn001" target="_blank">*</a>} and 95% confidence intervals of dying or being lost from treatment.</p

TB disease of RR-TB patients at enrolment^{^}, laboratory results.

<p>TB disease of RR-TB patients at enrolment^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0164974#t003fn001" target="_blank">^</a>}, laboratory results.</p

MOESM1 of Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa

Additional file 1: Table S1. Summary of third-line patients transferred in from clinical trials (n=10)